These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27009624)

  • 1. SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?
    Wilding J
    Lancet Diabetes Endocrinol; 2016 May; 4(5):379-81. PubMed ID: 27009624
    [No Abstract]   [Full Text] [Related]  

  • 2. [The combination of GLP-1 analogs and SGLT2 inhibitors : new perspectives ?].
    Ritz C; Jaafar J; Philippe J
    Rev Med Suisse; 2017 May; 13(565):1134-1139. PubMed ID: 28639755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
    Brunton SA
    Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
    Basile JN
    J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].
    Zechmann S
    Praxis (Bern 1994); 2016 Mar; 105(6):349-50. PubMed ID: 26980688
    [No Abstract]   [Full Text] [Related]  

  • 6. [SGLT2 inhibition in type 2 diabetes. New study data for reducing cardiovascular risk].
    MMW Fortschr Med; 2015 Oct; 157(18):86-7. PubMed ID: 26985517
    [No Abstract]   [Full Text] [Related]  

  • 7. SGLT2 inhibitors: new reports.
    Med Lett Drugs Ther; 2015 Oct; 57(1479):139-40. PubMed ID: 26445203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular safety of therapies for type 2 diabetes.
    Gupta P; White WB
    Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results from Cardiovascular Outcome Trials in Diabetes.
    Muñoz Torres M; Muñoz Garach A
    Endocrinol Nutr; 2016; 63(7):317-9. PubMed ID: 27324936
    [No Abstract]   [Full Text] [Related]  

  • 10. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
    Chrysant SG
    Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EMPA-REG OUTCOME: The Nephrologist's Point of View.
    Wanner C
    Am J Med; 2017 Jun; 130(6S):S63-S72. PubMed ID: 28526179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose transporter 2 inhibitors in type 2 diabetes mellitus: navigating between Scylla and Charybdis.
    Machado UF; Corrêa-Giannella ML
    Expert Opin Emerg Drugs; 2014 Mar; 19(1):5-9. PubMed ID: 24397354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors in CKD].
    Insalaco M; Zanoli L; Rastelli S; Lentini P; Rapisarda F; Fatuzzo P; Castellino P; Granata A
    G Ital Nefrol; 2015; 32(4):. PubMed ID: 26252258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes.
    Tamura K; Wakui H; Azushima K; Uneda K; Umemura S
    Hypertens Res; 2016 Jun; 39(6):396-8. PubMed ID: 26818654
    [No Abstract]   [Full Text] [Related]  

  • 15. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison chart of SGLT2 inhibitors.
    Med Lett Drugs Ther; 2017 Jan; 59(1513):e26. PubMed ID: 28118654
    [No Abstract]   [Full Text] [Related]  

  • 17. Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus.
    Guthrie RM
    Postgrad Med; 2013 May; 125(3):21-32. PubMed ID: 23748504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiological explanation of cardiovascular benefits of sodium-glucose cotransporter-2 inhibitors by neurotrophic theory.
    Hristova M
    Med Hypotheses; 2017 May; 102():61-64. PubMed ID: 28478833
    [No Abstract]   [Full Text] [Related]  

  • 19. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
    Misra M
    J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus.
    Tang H; Fang Z; Wang T; Cui W; Zhai S; Song Y
    Am J Cardiol; 2016 Dec; 118(11):1774-1780. PubMed ID: 27666177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.